1.94
2.02%
-0.04
eFFECTOR Therapeutics Inc Aktie (EFTR) Neueste Nachrichten
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.35% - MSN
MSN
eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update - Yahoo Finance
Yahoo Finance
eFFECTOR Therapeutics (NASDAQ:EFTR) Trading Up 1.5% - Defense World
Defense World
eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update - Yahoo Finance
Yahoo Finance
Head to Head Survey: eFFECTOR Therapeutics (NASDAQ:EFTR) versus COMPASS Pathways (NASDAQ:CMPS) - Defense World
Defense World
eFFECTOR Therapeutics to Participate in Upcoming Investor Conference
GlobeNewswire Inc.
eFFECTOR Therapeutics (EFTR) Plunges 82% as NSCLC Study Fails
Zacks Investment Research
eFFECTOR Therapeutics (EFTR) Plunges 82% as NSCLC Study Fails - Zacks Investment Research
Zacks Investment Research
Dow Dips Over 200 Points; RPM International Shares Fall After Q3 Results
Benzinga
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Nasdaq Surges 1%; ConAgra Brands Posts Upbeat Earnings
Benzinga
Dow Jumps Over 100 Points; US Jobless Claims Increase To 221,000
Benzinga
eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
GlobeNewswire Inc.
Dow Jumps Over 100 Points; US Jobless Claims Increase To 221,000 - Allurion Technologies (NYSE:ALUR), eFF - Benzinga
Benzinga
Effector Therapeutics' Stock Issuance Capped: Navigating the Lincoln Park Agreement's Exchange Limit - TipRanks.com - TipRanks
TipRanks
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire Inc.
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - Yahoo Finance
Yahoo Finance
eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
GlobeNewswire Inc.
Does eFFECTOR Therapeutics, Inc. (EFTR) Have the Potential to Rally 814.53% as Wall Street Analysts Expect?
Zacks Investment Research
Does eFFECTOR Therapeutics, Inc. (EFTR) Have the Potential to Rally 814.53% as Wall Street Analysts Expect? - Yahoo Finance
Yahoo Finance
eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
GlobeNewswire Inc.
eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under ... - Yahoo Finance
Yahoo Finance
(EFTR) Investment Analysis and Advice - Stock Traders Daily
Stock Traders Daily
Dow Tumbles Over 200 Points; US Trade Gap Narrows In November
Benzinga
eFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024
GlobeNewswire Inc.
eFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024 - GlobeNewswire
GlobeNewswire
Why LumiraDx Shares Are Trading Lower By Over 30%; Here Are 20 Stocks Moving Premarket
Benzinga
Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
Why Green Giant Shares Are Trading Lower By Around 37%; Here Are 20 Stocks Moving Premarket
Benzinga
Why Green Giant Shares Are Trading Lower By Around 37%; Here Are 20 Stocks Moving Premarket - Markets Insider
Markets Insider
eFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients
GlobeNewswire Inc.
eFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts ... - Yahoo Finance
Yahoo Finance
The role of STRIs in cancer - Drug Target Review
Drug Target Review
eFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update - Yahoo Finance
Yahoo Finance
BioTechnology Innovators Honored in 3rd Annual BioTech Breakthrough Awards Program - GlobeNewswire
GlobeNewswire
3 Promising Biotech Stocks That Will Make Early Investors Rich - InvestorPlace
InvestorPlace
eFFECTOR Therapeutics Announces $8.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewswire
GlobeNewswire
ASCO 2023 – Deep And Early Responses Lift Hopes At Effector - Scrip
Scrip
Investors in eFFECTOR Therapeutics (NASDAQ:EFTR) from a year ago are still down 35%, even after 77% gain this ... - Yahoo Finance
Yahoo Finance
Why Is eFFECTOR Therapeutics (EFTR) Stock Up 75% Today? - InvestorPlace
InvestorPlace
3 Penny Stocks That Could Turn $1000 into $10000 in a Year - InvestorPlace
InvestorPlace
eFFECTOR Therapeutics Shares Fall After Data From COVID-19 Treatment Trial - Yahoo Finance
Yahoo Finance
eFFECTOR Therapeutics to Present at 2023 BIO CEO & Investor Conference - Yahoo Finance
Yahoo Finance
eFFECTOR Therapeutics Shares Jump After Clinical Update Of Investigational Cancer Drug - Yahoo Finance
Yahoo Finance
First Patient With Lung Cancer Treated in Phase 2b Tomivosertib Trial - Curetoday.com
Curetoday.com
EFTR Stock Price and Chart — NASDAQ:EFTR — TradingView - TradingView
TradingView
What's Going On With eFFECTOR Therapeutics Stock Today? - Yahoo Finance
Yahoo Finance
SPAC Attack: The 10 biggest in biotech - Fierce Biotech
Fierce Biotech
eFFECTOR Therapeutics (EFTR) Stock Price, News & Analysis - MarketBeat
MarketBeat
Press Release Distribution and Management - GlobeNewswire
GlobeNewswire
Kapitalisierung:
|
Volumen (24h):